Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast biopsy & localization cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 19 | 1,094 | 39% |
| 2020 | 11 | 816 | 46% |
| 2021 | 16 | 948 | 51% |
| 2022 | 10 | 795 | 56% |
| 2023 | 14 | 878 | 59% |
| 2024 | 16 | 918 | 62% |
| 2025 from claims | – | 889 719–1,044 | 63% |
| 2026 forecast | – | 926 725–1,163 | 63% |
| 2027 forecast | – | 947 702–1,252 | 64% |
| 2028 forecast | – | 968 685–1,336 | 64% |
| 2029 forecast | – | 989 672–1,418 | 65% |
| 2030 forecast | – | 1,011 662–1,500 | 65% |
Image-guided breast biopsy and marker/localization placement. Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 84% of the cases CMS names in Maine; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 288 | 16,847+0.4%/yr | +0.4%/yr | 9.9 | 43% | 18,000 in 2030+1.1%/yr |
| Pennsylvania | 180 | 9,684−1.2%/yr | −1.2%/yr | 7.6 | 8% | 10,100 in 2030+0.8%/yr |
| Massachusetts | 117 | 7,183−0.3%/yr | −0.3%/yr | 8.0 | 12% | 8,190 in 2030+2.2%/yr |
| New Jersey | 124 | 7,0630%/yr | 0%/yr | 7.1 | 39% | 8,480 in 2030+3.1%/yr |
| Connecticut | 40 | 2,686−4.5%/yr | −4.5%/yr | 8.7 | 23% | 2,760 in 2030+0.5%/yr |
| Rhode Island | 25 | 1,437+8.2%/yr | +8.2%/yr | 17.1 | 37% | 1,840 in 2030+4.2%/yr |
| New Hampshire | 20 | 1,151−0.9%/yr | −0.9%/yr | 5.3 | 19% | 1,410 in 2030+3.4%/yr |
| Vermont | 13 | 477−0.9%/yr | −0.9%/yr | 4.4 | 0% | 1,320 in 2030+18%/yr |
Breast biopsy & localization in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
Exact Sciences leads with 67% of company spending on these surgeons in 2025, −7 pts on 2024.
In 2025, 9 companies reported engagement with Maine’s surgeons worth $5,100 in consulting, speaking, meals and travel tied to these products, about $319 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.